Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of “Buy” from Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been given an average recommendation of “Buy” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $43.11.

A number of equities analysts recently issued reports on DYN shares. Jefferies Financial Group upped their price target on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, May 20th. Oppenheimer reiterated an “outperform” rating and set a $47.00 price target on shares of Dyne Therapeutics in a report on Monday, May 6th. JPMorgan Chase & Co. raised their price target on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. Morgan Stanley assumed coverage on Dyne Therapeutics in a research report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price objective on the stock. Finally, Chardan Capital lifted their target price on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, May 21st.

Dyne Therapeutics Trading Up 5.3 %

Shares of NASDAQ:DYN opened at $43.38 on Friday. The stock has a fifty day simple moving average of $36.96 and a two-hundred day simple moving average of $29.58. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $45.46. The stock has a market capitalization of $3.79 billion, a price-to-earnings ratio of -10.93 and a beta of 1.07.

Insider Activity

In related news, COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction on Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the completion of the sale, the chief operating officer now owns 148,792 shares of the company’s stock, valued at $5,256,821.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,590 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $30.23, for a total value of $48,065.70. Following the transaction, the senior vice president now directly owns 115,105 shares in the company, valued at $3,479,624.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Susanna Gatti High sold 10,163 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $35.33, for a total transaction of $359,058.79. Following the sale, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at approximately $5,256,821.36. The disclosure for this sale can be found here. Insiders have sold 202,133 shares of company stock valued at $6,500,387 in the last ninety days. 20.77% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC raised its stake in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares during the period. Wetzel Investment Advisors Inc. bought a new stake in Dyne Therapeutics during the 1st quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. lifted its holdings in Dyne Therapeutics by 355.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after purchasing an additional 5,541 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after purchasing an additional 1,291 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth $172,000. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.